Prelude Therapeutics Incorporated IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Prelude Therapeutics Incorporated | PRLD - NASDAQ |
$17.00-$19.00 | $19.00 | $25.23 | 8.3 million | 9/25/2020 |
| Morgan Stanley, Goldman Sachs, BofA Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-09-04 Terms Added 2020-09-21 | ||||||
Prelude Therapeutics Incorporated Quote & Chart - Click for current quote - PRLD
IPO Boutique aggregates information on public companies and private companies, such as "PRLD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Prelude Therapeutics Incorporated (adapted from Prelude Therapeutics Incorporated prospectus):
They are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PRLD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.